. 2022 Mar 1;33(4):947–953. doi: 10.1007/s00192-022-05094-9

Table 2.

Cure rates at the 1-, 5-, 10-, 15-, 17- and 20-year follow-up visits

	1 yr	5 yr	10 yr	15 yr	17 yr	20 yr	p value
Subjective outcomes Satisfied (N)	92% (46/50)	92% (46/50)	89.3% (42/47)	89.1% (41/46)	89.1% (41/46)	88.8% (32/36)	0.98 ^a 0.50 ^b
Objectively cured Objectively cured (at stress test)	94% (47/50)	94% (47/50)	93.6% (44/47)	91.3% (42/46)	91.3% (42/46)	91.7% (33/36)	0.98 ^a 0.48 ^b
De novo overactive bladder Onset of OAB	12% (6/50)	12% (6/50)	19.1% (9/47)	23.9% (11/46)	32.6% (15/46)	41.6% (15/36)	0.004 ^a

1 yr

5 yr

10 yr

15 yr

17 yr

20 yr

p value

Subjective outcomes

Satisfied (N)

92% (46/50)

89.3% (42/47)

89.1% (41/46)

88.8% (32/36)

0.98 ^a 0.50 ^b

Objectively cured

Objectively cured (at stress test)

94% (47/50)

93.6% (44/47)

91.3% (42/46)

91.7% (33/36)

0.98 ^a 0.48 ^b

De novo overactive bladder

Onset of OAB

12% (6/50)

19.1% (9/47)

23.9% (11/46)

32.6% (15/46)

41.6% (15/36)

0.004 ^a

^aChi-square test; ^bchi square test for trend

The null hypothesis is that there is no association between the cure rate of TVT and the time